tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

STE · Q4 2025 Earnings

Steris

Reported May 14, 2025

30-second summary

Steris reported Q4 FY2025 revenue of $1.48B (+4.3% YoY) and non-GAAP EPS of $2.74, with Healthcare (+4.9%) and AST (+9.2%) offsetting a 6.9% Life Sciences decline. FY2026 guidance calls for 6–7% revenue growth and $9.90–$10.15 EPS (7–10% growth), but absorbs an estimated $30M net tariff hit and ~$40M of ETO-related cash payment that pulls free cash flow down to ~$770M from FY2025's record $787M. (Separately, the P&L absorbed a $48.15M Illinois EO litigation settlement charge in Q4 FY2025.) Management's tone is notably defensive for a company guiding double-digit EPS growth — bioprocessing recovery has been explicitly tempered and tariff mitigation is described as ongoing rather than resolved.

Headline numbers

EPS

Q4 FY2025

$2.74

Revenue

Q4 FY2025

$1.48B

+4.3% YoY

Gross margin

Q4 FY2025

43.3%

Operating margin

Q4 FY2025

14.6%

Key financials

Q4 FY2025
MetricQ4 FY2025YoY
Revenue$1.48B+4.3%
EPS$2.74—
Gross margin43.3%—
Operating margin14.6%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Healthcare$1.057B+4.9%
Applied Sterilization Technologies (AST)$0.274B+9.2%
Life Sciences$0.149B-6.9%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
United States$1.079B+4.1%
International$0.364B+0.8%
Healthcare Segment Operating Margin26.5%—
AST Segment Operating Margin44.6%—
Life Sciences Segment Operating Margin43.5%—
Recurring Revenue$1,109.5M—
Consumables Revenue$430.0M—
Service Revenue$679.5M—
Capital Equipment Revenue$371.1M—
Total Backlog - Continuing Operations$452.9M—

Management tone

Management's posture across the FY2025 close is markedly more defensive than the FY2026 EPS growth rate would suggest, with three distinct shifts visible across the prepared remarks, Q&A, and FY2026 guide construction.

Bioprocessing recovery framing has softened. After describing a "really strong rebound late in the year" in Life Sciences capital orders, management pivoted to "let's take a little more conservative approach on how aggressively some of the bioprocessing is going to recover." That conservative posture is now embedded in the FY2026 guide despite the Q4 FY2025 exit momentum. The signal: customer inventory dynamics remain unresolved, and management would rather underwrite the FY2026 plan to a slower curve than risk another mid-year reset.

Tariff exposure was repositioned from "minimal" to "active mitigation required." The historical framing emphasized "85% of the products sold in the U.S. coming from North American manufacturing" as a structural defense. The FY2026 disclosure introduces a $30M net pre-tax headwind with the explicit caveat that the gross number is "significantly higher than that. Obviously, there's a lot to be done to mitigate." This is the company telling investors that the previously-cited manufacturing footprint is not the full firewall it was implied to be.

Onshoring as a tailwind was downplayed. When prompted, management characterized policy-driven onshoring opportunity as "probably the latter…it takes time" — effectively dismissing the bull-case narrative that regulatory shifts would drive volume into AST and Healthcare. Realistic, but it removes a thesis pillar that some sell-side models likely carried.

Free cash flow trajectory inverts despite revenue growth. FY2025's record $787M FCF was driven by "significant working capital improvements, in particular inventory" — non-repeating. FY2026 FCF guide of ~$770M absorbs ~$40M of ETO-related cash payment (per Mike's Q&A comment that "we anticipate paying a $40 million legal settlement for ETO") on top of the absence of working capital tailwind. Note this is distinct from the $48.15M Illinois EO litigation settlement charge already booked to the FY2025 P&L. The headline EPS growth of 7–10% masks a cash-conversion story going the wrong direction.

Recurring themes management leaned on this quarter:

Tariff mitigation and strategic supply chain repositioningHealthcare capital equipment orders strong but execution timing uncertainBioprocessing volatility and lumpy demand patternsRecurring revenue (consumables/services) as growth engineOperating leverage through productivity and pricing offset labor inflationM&A capacity exists but selectivity remains high

Risks management surfaced:

Tariff exposure of $30M net in FY26, split evenly between China and global 10% tariffBioprocessing demand lumpiness and customer inventory reassessmentPharma capital equipment orders uncertainty in early FY25 dried up ordersETO litigation settlement of $40M impacting FY26 free cash flowRegulatory complexity limiting onshoring relocation speed

What to watch into next quarter

Tariff mitigation traction — management said the $30M is a "net number" with gross materially higher; watch FY2026 Q1 commentary for whether mitigation actions are tracking or whether the net number creeps up

Bioprocessing order pattern — Life Sciences declined 6.9% in Q4 FY2025; watch whether the "lumpy" demand pattern shows another leg down or whether late-FY2025 rebound persists into FY2026 Q1

Healthcare capital equipment execution — orders described as strong with "pretty good backlog"; watch whether $452.9M backlog converts on the expected cadence given execution timing was flagged as uncertain

AST segment growth durability — 9.2% growth at 44.6% op margin is the standout; watch whether segment guide of 6–7% proves conservative or whether the FY2025 exit rate decelerates

ETO settlement cash timing — ~$40M cash payment embedded in FY2026 FCF guide; watch for any additional litigation disclosure that would pressure the ~$770M FCF figure further

Sources

  1. Steris Q4 FY2025 press release, SEC filing: https://www.sec.gov/Archives/edgar/data/1757898/000175789825000004/ste03312025ex991.htm
  2. Steris Q4 FY2025 earnings conference call transcript (May 15, 2025), prepared remarks and Q&A.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.